



**VCR PARK**  
Harmonizing Innovation

In partnership with



*When your patients have limited therapeutic or clinical trial options consider*

## **The CUREMATCH** **Clinical Decision Support Platform** *A holistic mechanism for expanding therapeutic options*



- **ONLY CureMatch** provides biology driven custom combination therapy options which are scored, filtered & prioritised based on the fitness of molecular matching
- A real time system to correlate treatment decisions for your patients with an AI driven and manually curated reference knowledge repository
- Developed and validated by globally renowned precision oncology experts



## Why CUREMATCH ?

CureMatch is a powerful adjunct to therapeutic decision making because it provides options for **combining therapies for approved indications** with those which are **off-label but have been approved** for other cancers. The Algorithm references genomics, pharmacologic, drug mechanisms, clinical trial, resistance and toxicity data to curate the best potential options.

## Who would benefit from CUREMATCH ?

Consider CureMatch for the following scenarios:

- Where there are **no applicable clinical trials** in India or if patients do not meet inclusion criteria
- Patients who are withdrawn from a clinical trial due to toxicity or response
- Have rare cancers with few treatment options
- Aggressive tumors that don't seem to be responding to standard lines of therapy
- Advanced systemic tumors that are resistant to standard therapy.
- To evaluate a more cost-effective treatment combination

## Isn't NGS enough?

Standard molecular testing reports contain drugs targeted for a particular mutation

CureMatch is **complementary to NGS** lab services, which serve as inputs to initiate CureMatch analysis.

Assesses & quantifies

CureMatch assesses drugs in **custom combinations systematically** and quantifies the **fitness of molecular matching** of each therapy option.

300 available cancer drugs

Of the over 4.5 million possible combinations of 300 available cancer drugs, CureMatch can present known and unknown **treatment options**.

Molecular therapy matching

The customized unique combinations account for more than **99% of top scoring molecular therapy matches per patient with any cancer**.

Knowledge database

Matching is based on an expert-guided manually-curated **algorithm**, which presents options from an extensive knowledge database **curated for over 7 years** and continuously updated.

Scored & filtered

Only CureMatch provides biology driven combination therapy options which are **scored, filtered & prioritised** based on relevance.



## About CUREMATCH



San Diego-based digital health company that guides oncologists in the selection of **personalized combination therapies**, using supercomputing and the latest discoveries in **genomics and proteomics**.




Customized molecularly matched therapy options for advanced cancer patients after NGS testing which are derived from a validated & **expertly curated database**



CureMatch provides a **scored and ranked listing** novel combination cancer therapies (monotherapy, 2-drug combinations, and 3- drug combinations), based on the biomarkers of the patient's unique molecular tumor profile



CureMatch **Decision Support System** enables oncologists with actionable insights based on the patient's molecular profile towards advanced cancer treatment options



## About VCR Park



Brings together high caliber stakeholders on a common platform and **provides appropriate state-of-the-art lab and knowledge infrastructure** to conduct **world-class translational oncology projects**



Unprecedented mission-focused **integrative collaborations** to **translate innovative ideas** in support of improving cancer diagnoses, treatment, and care


Provides highly effective project management and business services required for **end-to-end execution of projects** in a **time- and cost-efficient manner**




India's **first cancer-focused ecosystem**



## How VCR Park is collaborating with CUREMATCH to bring access to next-gen solutions for patients



## VCR Park & CUREMATCH Process



→ Cases will be reviewed in our digital precision tumor board once every 6 weeks on a voluntary basis.



## Team

### CUREMATCH



#### Razelle Kurzrock, MD

Chief medical advisor & Co-founder, CUREMATCH  
Director, Rare tumor clinic, UCSD

- A board-certified medical oncologist and a renowned expert in precision medicine
- With over **400 peer-reviewed publications**, she has a strong record of competitive grant funding
- Developed one of the largest Phase I clinical trial programs at **MD Anderson** Cancer Center, Texas
- Executive Committee of **Board of Directors**, National Comprehensive Cancer Network® (**NCCN®**)

### VCR Park



#### Himabindu Gaddipati, MD, EMTM

Chairman and MD, VCR Park  
CEO, Lumiseek

- Clinical hemato-oncologist and geneticist
- Over 2 decades of expertise in Basic science, Clinical trials, Precision medicine, Technology commercialization (**Wharton**), Regulation (**FDA**) and IP (**NCI**)
- Founder at Biolara Inc.
- Executive Director, Queens NRI Hospital, Visakhapatnam



#### Payal Keswarpu, MD, DNB

Pathology Lab Director, VCR Park

- Pathologist with **20 years** of experience in **molecular pathology** services and development of esoteric assays
- Experience in working with laboratories in **precision oncology** space in **US & India**
- Expertise in Quality management process and audit
- Established research **partnership** for oncology products and services with **academic and hospital-based programs**



Scan here for further details

## Contact Us



[cmsupport@vcrpark.com](mailto:cmsupport@vcrpark.com)